<DOC>
	<DOCNO>NCT02401347</DOCNO>
	<brief_summary>The aim single-arm phase II clinical trial evaluate anti-cancer activity Talazoparib ( also know BMN 673 ) patient advance breast cancer specific genetic tumor genomic alteration . Patients either triple-negative HER2-negative breast cancer eligible .</brief_summary>
	<brief_title>Talazoparib Beyond BRCA ( TBB ) Trial</brief_title>
	<detailed_description>Talazoparib ( BMN 673 ) novel , dual-mechanism PARP inhibitor potently inhibit PARP enzyme effectively trap PARP DNA . Talazoparib show promising single-agent anti-tumor efficacy several BRCA1/2 mutation-associated advance cancer . The efficacy PARP inhibition BRCA1/2 wild-type TNBC homologous recombination ( HR ) defect breast tumor mutation non-BRCA1/2 HR pathway gene currently unknown . This Phase 2 trial ( TBB ) explore activity single agent talazoparib BRCA1/2 wild-type BC patient use optimal Simon two-stage design . Eligible subject assign one two parallel cohort : 1 ) Cohort A : Subjects ( n=29 ) advance TNBC underlie HR defect assess HRD assay , 2 ) Cohort B : Subjects ( n=29 ) advance HER2-negative BC somatic germline mutation non-BRCA1/2 HR pathway gene . Gene mutation interest : PTEN , PALB2 , CHEK2 , ATM , NBN , BARD1 , BRIP1 , RAD50 , RAD51C , RAD51D , MRE11 , ATR , Fanconi anemia complementation group gene ( FANCA , FANCC , FANCD2 , FANCE , FANCF , FANCG , FANCL ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>No deleterious germline BRCA1 BRCA2 mutation base full sequence comprehensive rearrangement test external reference laboratory ( Myriad Genetics ) ; patient variant unknown significance eligible Patients must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Must progress least 1 prior chemotherapy regimen treatment advance breast cancer ; upper limit number prior therapy An Eastern Cooperative Oncology Group ( ECOG ) performance status 02 An estimate life expectancy least 16 week Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) ; liver function abnormality due hepatic metastasis , AST ALT = &lt; 5 x ULN Total serum bilirubin = &lt; 1.5 x ULN ( = &lt; 3 x ULN Gilbert 's syndrome ) Calculated creatinine clearance &gt; = 30 mL/min serum creatinine = &lt; 1.5 mg/dl Hemoglobin &gt; = 9.0 g/dL last transfusion least 14 day day 1 study drug Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Able take oral medication Willing able provide write , sign informed consent nature study explain , prior researchrelated procedure Sexually active patient childbearing potential must willing use acceptable method contraception intrauterine device double barrier contraception treatment 30 day last dose study drug Females childbearing potential must negative serum pregnancy test screen willing additional serum pregnancy test study ; female consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior screening , total hysterectomy Willing able comply study procedure COHORT A SPECIFIC ELIGIBILITY CRITERIA : Histologically confirm metastatic recurrent triplenegative breast cancer ( define estrogen receptor = &lt; 5 % , progesterone receptor = &lt; 5 % , HER2negative via immunohistochemistry [ IHC ] fluorescent situ hybridization [ FISH ] ) An HRD score &gt; = 42 Myriad HRD Assay assess tumor biopsy sample ; case obtain adequate metastatic tumor biopsy possible , assess HRD score primary breast tumor COHORT B SPECIFIC ELIGIBILITY CRITERIA : Histologically confirm metastatic recurrent HER2negative ( via IHC FISH ) breast cancer Deleterious germline somatic mutation implicate homologous recombination ( HR ) pathway , exclude BRCA1 BRCA2 , base germline multiplex gene test direct tumor next generation DNA sequencing . Genes interest include : PTEN , PALB2 , CHEK2 , ATM , NBN , BARD1 , BRIP1 , RAD50 , Rad51c , Rad51d , MRE11 , ATR , FANCA , FANCC , FANCD2 , FANCE , FANCF , FANCG , FANCL , plus HRrelated gene discretion primary investigator . Any patient deleterious mutation BRCA1 BRCA2 Prior treatment platinum agent ( i.e . cisplatin carboplatin ) Prior treatment PARP inhibitor Nonmeasurable disease Pregnant nursing patient Any anticancer therapy within past 21 day first day treatment Brain central nervous system ( CNS ) metastases progressive symptomatic , previously resect irradiate , site measurable disease Other malignancy either active patient receive treatment last five year exclude nonmelanoma skin cancer carcinoma situ cervix Radiation therapy last 14 day Known human immunodeficiency virus positive Known active hepatitis C virus , know active hepatitis B virus Use investigational product ( IP ) investigational medical device within 28 day day 1 study drug Major surgery require prolong hospitalization recovery within 21 day day 1 study drug Concurrent disease condition would interfere study participation safety , follow : Active , clinically significant infection either grade &gt; 2 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 requiring use parenteral antimicrobial agent within 7 day day 1 study drug Clinically significant bleeding diathesis coagulopathy , include know platelet function disorder Known hypersensitivity component BMN 673</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>PALB2 mutation</keyword>
	<keyword>BRIP1 mutation</keyword>
	<keyword>BARD1 mutation</keyword>
	<keyword>Rad51c mutation</keyword>
	<keyword>PTEN mutation</keyword>
	<keyword>CHEK2 mutation</keyword>
	<keyword>ATM mutation</keyword>
	<keyword>NBN mutation</keyword>
	<keyword>Rad51d mutation</keyword>
	<keyword>Rad50 mutation</keyword>
	<keyword>MRE11 mutation</keyword>
	<keyword>FANC mutation</keyword>
	<keyword>HRD assay score</keyword>
	<keyword>ATR mutation</keyword>
</DOC>